Company: IMNN
Filing Date: 2025-05-19
Form Type: S-1/A
Source: 0001641172-25-011388
Chunk: 23

Company: Imunon, Inc.
Filing Date: 2025-05-19
Form: S-1/A
Chunk 23
---
 Staff would grant our request for continued listing.

If our Common Stock were to be delisted by Nasdaq, it may be eligible for quotation on an over-the-counter quotation system or on the pink sheets. Upon any such delisting, our Common Stock would become subject to the regulations of the SEC relating to the market for penny stocks. A penny stock is any equity security not traded on a national securities exchange that has a market price of less than $5.00 per share. The regulations applicable to penny stocks may severely affect the market liquidity for our Common Stock and could limit the ability of stockholders to sell securities in the secondary market. In such a case, an investor may find it more difficult to dispose of or obtain accurate quotations as to the market value of our Common Stock, and there can be no assurance that our Common Stock will be eligible for trading or quotation on any alternative exchanges or markets.

| 8 |

Delisting from Nasdaq could adversely affect our ability to raise additional financing through public or private sales of equity securities, would significantly affect the ability of investors to trade our securities and would negatively affect the value and liquidity of our Common Stock. Delisting could also have other negative results, including the potential loss of confidence by employees, the loss of institutional investor interest and fewer business development opportunities.

Nasdaq may delist our Common Stock for public interest concerns.

Because
of the highly dilutive nature of this offering and the high risk of our Common Stock falling back into noncompliance with the continuing
listing standards of Nasdaq, Nasdaq may delist our Common Stock for public interest concerns, even if we are able to regain compliance
for continued listing on Nasdaq under the minimum closing bid price requirement, as described in the risk factor above. We are aware
of public disclosures made by other Nasdaq-listed companies disclosing that such companies received notification letters from Nasdaq
indicating that Nasdaq determined to delist such companies as a result of public interest concerns arising from the issuance of warrants
with similar terms to, and similar potential dilutive impact as, the common warrants in this offering.

We will need to raise additional capital to fund our planned future operations, and we may be unable to secure such capital without significant dilutive financing transactions, or at all. If we are not able to raise additional capital, we may not be able to complete the development, testing and commercialization of our drug candidates and will not be able to continue as a going concern.

We have not generated significant revenue and have incurred significant net losses